Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Most Undervalued Oncolytics Company On The Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Oct 05, 2023 5:28pm

56 Views

Post# 35672049

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The Most Undervalued Oncolytics Company On The Nasdaq

I am quite aware of what the company is doing. I Do my own research. Don't need yalls commentaries here. Again you folks think what you post on here has changed the course the BOD has taken... lol. I guess you pumpers have to keep each other pumped or stroke each other's ego or something. This company has a very good chance of doing something down the road.

<< Previous

Bullboard Posts

Next >>

UniDoc brings AI-powered H3 Health Cube to Italy